Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial
Eleanor M Hudson,Samantha Noutch,Joanne Webster,Sarah R Brown,Florien W Boele,Omar Al-Salihi,Helen Baines,Helen Bulbeck,Stuart Currie,Sharon Fernandez,Jane Hughes,John Lilley,Alexandra Smith,Catherine Parbutt,Finbar Slevin,Susan Short,David Sebag-Montefiore,Louise Murray,Hudson,E. M.,Noutch,S.,Webster,J.,Brown,S. R.,Boele,F. W.,Al-Salihi,O.,Baines,H.,Bulbeck,H.,Currie,S.,Fernandez,S.,Hughes,J.,Lilley,J.,Smith,A.,Parbutt,C.,Slevin,F.,Short,S.,Sebag-Montefiore,D.,Murray,L.
DOI: https://doi.org/10.1136/bmjopen-2023-078926
IF: 3.006
2024-03-10
BMJ Open
Abstract:Introduction Glioblastoma (GBM) is the most common adult primary malignant brain tumour. The condition is incurable and, despite aggressive treatment at first presentation, almost all tumours recur after a median of 7 months. The aim of treatment at recurrence is to prolong survival and maintain health-related quality of life (HRQoL). Chemotherapy is typically employed for recurrent GBM, often using nitrosourea-based regimens. However, efficacy is limited, with reported median survivals between 5 and 9 months from recurrence. Although less commonly used in the UK, there is growing evidence that re-irradiation may produce survival outcomes at least similar to nitrosourea-based chemotherapy. However, there remains uncertainty as to the optimum approach and there is a paucity of available data, especially with regards to HRQoL. Brain Re-Irradiation Or Chemotherapy (BRIOChe) aims to assess re-irradiation, as an acceptable treatment option for recurrent IDH-wild-type GBM. Methods and analysis BRIOChe is a phase II, multi-centre, open-label, randomised trial in patients with recurrent GBM. The trial uses Sargent's three-outcome design and will recruit approximately 55 participants from 10 to 15 UK radiotherapy sites, allocated (2:1) to receive re-irradiation (35 Gy in 10 daily fractions) or nitrosourea-based chemotherapy (up to six, 6-weekly cycles). The primary endpoint is overall survival rate for re-irradiation patients at 9 months. There will be no formal statistical comparison between treatment arms for the decision-making primary analysis. The chemotherapy arm will be used for calibration purposes, to collect concurrent data to aid interpretation of results. Secondary outcomes include HRQoL, dexamethasone requirement, anti-epileptic drug requirement, radiological response, treatment compliance, acute and late toxicities, progression-free survival. Ethics and dissemination BRIOChe obtained ethical approval from Office for Research Ethics Committees Northern Ireland (reference no. 20/NI/0070). Final trial results will be published in peer-reviewed journals and adhere to the ICMJE guidelines. Trial registration number ISRCTN60524.
medicine, general & internal